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Abstract
Background: The relationship between BMI and leptin has been studied extensively in the past,
but previous reports in postmenopausal women have not been conducted under carefully
controlled dietary conditions of weight maintenance using precise measures of body fat
distribution. The aim of the present study was to examine the association between serum leptin
concentration and adiposity as estimated by BMI and dual energy x-ray absorptiometry (DEXA)
measures (percent body fat, central and peripheral fat, and lean mass) in postmenopausal women.
Methods: This study was conducted as a cross-sectional analysis within the control segment of a
randomized, crossover trial in which postmenopausal women (n = 51) consumed 0 (control), 15
(one drink), and 30 (two drinks) g alcohol (ethanol)/d for 8 weeks as part of a controlled diet. BMIs
were determined and DEXA scans were administered to the women during the 0 g alcohol
treatment, and a blood sample was collected at baseline and week 8 of each study period for leptin
analysis.
Results and discussion: In multivariate analysis, women who were overweight (BMI > 25 to ≤ 30
kg/m2) had a 2-fold increase, and obese women (BMI > 30 kg/m2) had more than a 3-fold increase
in serum leptin concentrations compared to normal weight (BMI ≤25 kg/m2) women. When the
models for the different measures of adiposity were assessed by multiple R2, models which included
percent body fat explained the highest proportion (approximately 80%) of the serum leptin
variance.
Conclusion:  Under carefully controlled dietary conditions, we confirm that higher levels of
adiposity were associated with higher concentrations of serum leptin. It appears that percent body
fat in postmenopausal women may be the best adiposity-related predictor of serum leptin.
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Background
Natural menopause, a normal aspect of aging, may influ-
ence risk of breast cancer [1], the leading contributor to
cancer incidence in women in the United States (US).
Menopause is associated with a progressive gain in body
weight and an increased tendency for central adiposity
with advancing age [2]. Thus, the role of adiposity and
lean body mass in postmenopausal breast cancer is
important because three-fourths of breast cancer cases and
deaths occur in women over 50 years of age [3], and gen-
eral obesity [4] as well as central adiposity [5,6] are risk
factors for postmenopausal breast cancer. While it is not
completely clear how obesity results in postmenopausal
breast carcinogenesis, it has been ascribed to an excess of
circulating estrogens resulting from the conversion of
androgens into estrogens through aromatization in adi-
pose tissue [7]. Another possibility is that other hormones
produced by the adipocytes, such as leptin, may play a
critical role in the increased breast cancer risk associated
with obesity [8,9]. Circulating leptin concentration is
highly correlated with body mass index (BMI) [10,11],
and percent body fat [8,9], but less is known about the
relations between body fat distribution and lean mass to
leptin concentrations in postmenopausal women under
carefully controlled dietary conditions of weight mainte-
nance. This is important because both diet and exercise
alter serum leptin levels [12-14].
In various in vitro models, leptin acts as a growth factor
and stimulates cellular proliferation, angiogenesis, motil-
ity, and invasion [15-20]. Leptin stimulates the growth of
breast cancer cell lines in vitro [18,20] and can induce the
expression of proteolytic enzymes which are essential for
breast cancer cell invasion [21]. Leptin has also been
shown to counteract the anti-tumorigenic activities of
anti-estrogens in breast cancer cells [22]. In this study, we
assessed the relationship of serum leptin concentrations
to adiposity as estimated by BMI, percent body fat, central
fat, peripheral fat, and lean mass. The study was con-
ducted under controlled dietary conditions in which the
women maintained stable weight. We hypothesized that
in postmenopausal women, after controlling for well-
known breast cancer risk factors, central fat would be
strongly associated with serum leptin concentrations and
the association with central body fat would be greater
than for BMI.
Materials and methods
Study design
This study was part of a randomized, crossover, interven-
tion trial of moderate alcohol supplementation in post-
menopausal women (n = 51). Details of the study design
and procedures have been published previously [23,24].
Briefly, subjects were assigned to three separate 8-wk
study periods during which they consumed a controlled
diet and were provided a beverage (orange juice) each day
that contained 0, 15, or 30 g alcohol (95% ethanol) in
random order. Each subject completed the three study
periods; each study period was separated by two-five week
washout periods. Total and regional adiposity measure-
ments were assessed during the fourth week of the control
treatment (0 g alcohol/day). DEXA (Lunar Corp., Model
DPX-L, Madison, WI) whole body scans were used for adi-
posity assessments; measures of BMI were taken on the
same day.
Subjects
Postmenopausal women were recruited by advertisement
from the communities surrounding the Beltsville Human
Nutrition Research Center, Beltsville, MD. The eligibility
criteria were: (1) women ≥ 50 y of age, (2) postmenopau-
sal (last menses > 12 months before the study started or
follicle stimulating hormone > 40,000 mIU/L, natural
menopause or hysterectomy with at least one ovary
intact), (3) not receiving hormone replacement therapy
(HRT), (4) not taking prescription medications that might
interfere with the study, (5) willing and able to consume
the diet prepared or approved by the Center and no other
foods or beverages, and (6) without personal or parental
history of alcohol abuse. The subjects were evaluated by a
physician and determined to be in good health with no
signs or symptoms of any disease or endocrine disorders.
This study was approved by the National Cancer Insti-
tute's Institutional Review Board and the Committee on
Human Research of the Johns Hopkins University
Bloomberg School of Hygiene and Public Health. All sub-
jects were fully informed of the study requirements and
were required to read and sign a consent form detailing
the objectives, risks, and benefits of the study. The sub-
jects were compensated for their participation.
Diets and feeding
All meals were prepared at the Beltsville Human Nutrition
Research Center from typical U.S. foods and served in a
seven-day menu cycle. Each day's diet provided 15%
energy as protein, 50% energy as carbohydrate, and 35%
energy as fat, with a polyunsaturated/monounsaturated/
saturated fat ratio of 0.6:1:1. Daily fiber intake was 10 g/
1,000 kcal, and daily cholesterol intake was 150 mg/1,000
kcal. Diets provided 100% of the U.S. recommended die-
tary allowances for vitamins and minerals [25]. The study
participants were weighed each weekday by study investi-
gators at the Beltsville facility, and energy intake was
adjusted to maintain constant body weight.
DEXA measurements
Body composition was determined by pencil beam dual
energy x-ray absorptiometry (Lunar Corp., Model DPX-L,
Madison, WI). Subjects were placed in a supine positionNutrition Journal 2007, 6:3 http://www.nutritionj.com/content/6/1/3
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with arms and legs close to their body for a whole body
scan following the manufacturer's recommended proto-
col. Whole body and regional lean mass (mass of bone
and nonfat soft tissue) and fat mass were determined
using the manufacturer's algorithm (software version
1.33).
Biological sample collection and analysis
During the last week of the control treatment, blood sam-
ples for leptin analysis were collected from fasting (> 12
hours) subjects before breakfast (6:30 AM to 9:00 AM) on
each of three non-consecutive days in each study period.
An equal volume of serum from each day's blood draw
was pooled for analysis. Serum was separated and aliq-
uots were frozen at -70°C. The laboratory methods for the
serum leptin measurements were described previously
[26]. Briefly, circulating leptin concentration was meas-
ured in duplicate by radioimmunoassays (RIA) using a
commercially available kit (Human Leptin RIA Kit; Linco
Research, St. Charles, MO) and quantified using a Cobra
Quantum Gamma Counter (Packard Instruments,
Downer Grove, IL). Standard reference materials were run
as assay controls with each experiment.
Statistical analysis
Serum leptin concentrations were log transformed using
the natural log. All estimates of means and the differences
between means were made using the log transformed lep-
tin values. In tables we report means and regression coef-
ficients returned to the original (arithmetic) scale.
Pearson and Spearman correlations between the different
DEXA measurements and BMI (kg/m2 calculated from
measured weight and height) were determined. Mean
serum leptin concentrations for BMI categories were esti-
mated using linear regression models that included a
series of indicator variables for three standard BMI catego-
ries (normal, ≤ 25 kg/m2; overweight, > 25 and ≤ 30 kg/
m2; or obese, > 30 kg/m2). BMI categories were also mod-
eled as ordinal variables with values 0, 1, and 2. Addi-
tional models estimated percent changes in serum leptin
concentrations per one-unit change in BMI, one-percent
change in total body fat (measured as percent body fat),
and 1000 g change in central, peripheral, or lean mass
modeled as continuous variables. All models included age
(continuous), parity (continuous), race (example, African
American, yes/no), age of menarche (less than 12, yes/
no), and family history of breast cancer (mother or full
sister with breast cancer, yes/no). One woman's breast
cancer information was missing and she was excluded
from models that included breast cancer history. Sensitiv-
ity models including her as having or not having a family
history of breast cancer did not change analysis conclu-
sions. In a second series of models (Model 2), we added
BMI to Model 1 as a covariate The addition of alcohol
group assignment order, study period, hysterectomy,
duration of menses, years since last menses, nulliparity,
and age at first birth (for those with children) did not
improve the precision of the estimates and these terms
were not included in the final models. There was no evi-
dence of effect modification as assessed by likelihood
ratio tests of model fit after the addition of cross-product
terms to models that included main effects. Throughout
the paper all P-values are two-sided nominal (unadjusted)
P-values. P-values for BMI and DEXA measurements were
determined using likelihood ratio tests comparing models
with the BMI or DEXA term of interest to models without
that term. Multiple R2 and F-tests were calculated from the
linear regression models. Statistical analyses were per-
formed using S-PLUS (S-PLUS version 6.2 for Windows,
Seattle, WA, Insightful Corporation; 2002).
Results
Fifty-one women successfully completed the entire study
and are included in the present analysis. The physical
characteristics and reproductive history of the subjects at
baseline are provided in Table 1. All the participants were
postmenopausal. Their ages ranged from 49.2 years to
78.8 years with a median of 58.2 years. Most (75%)
women were white, 22% were black, and 4% were Asian.
The median body weight was 73.2 kg (range, 42.1 kg to
117.4 kg); BMI ranged from 17.7 kg/m2 to 42.5 kg/m2
(median 26.9); and total body fat ranged from 7,942 g to
55,756 g (median, 26,808 g), while trunk, leg, and arm fat
were of progressively lesser magnitude. Descriptive statis-
tics for serum leptin concentrations are also presented in
Table 1.
Table 2 shows the geometric mean serum leptin concen-
trations by categories of BMI defined as normal weight,
overweight, and obese. As expected, we found a highly sig-
nificant trend for increased concentrations of leptin with
increasing levels of overweight or obesity (P < 0.0001).
Among obese subjects, serum leptin concentrations were
more than three-fold those seen in the normal weight sub-
jects.
Table 3 shows how much serum leptin concentration
changed for a one-unit increase of BMI, a one-percent
increase in body fat, and a one-kilogram increase in cen-
tral fat, peripheral fat, or lean body mass. For model 1
(adjusted for age, race, family history of breast cancer, par-
ity, and menarche < 12 years), we found statistically sig-
nificant increases in the concentrations of serum leptin for
all five measures of adiposity. For example, leptin
increased 7.8% (95% CI = 6.6%–9.0%) for each one-per-
cent increase in total body fat. This association held true
across different measures of adiposity: leptin increased
10.6% (95% CI = 8.3%–12.8%) for each one-kilogram
increase in peripheral fat, 11.9% (95% CI = 9.7%–14.2%)Nutrition Journal 2007, 6:3 http://www.nutritionj.com/content/6/1/3
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for each one-kilogram in central fat, 8.6% (95% CI =
3.8%–13.7%) for each one-kilogram increase in lean
mass, and 10.7% (95% CI = 8.2%–13.2%) for each one-
unit increase in BMI. Therefore, a one-unit change for
each of these adiposity measures was associated with a
substantial change in serum leptin. In Model 2, BMI was
added to the covariates in Model 1, and demonstrates that
percent body fat, central fat, and peripheral fat all pro-
vided additional predictive information about serum lep-
tin concentrations beyond BMI and the other covariates.
When multiple R2 was used to assess the strength of the
linear associations of the overall models to leptin (Table
3), the percent fat models explained the highest propor-
tion (over 80%) of the variance related to serum leptin
concentrations. Overall, the multiple R2s shown in Table
Table 2: Geometric mean serum hormone concentrations by categories of BMI
BMI CATEGORY
Normal weight Overweight Obese
BMI categories (BMI ≤ 25) (BMI > 25 to ≤ 30) (BMI > 30) P-trend††
N2 0 1 7 1 4
Model Mean, 95%, CI Mean, 95%, CI Mean, 95%, CI
Leptin, ng/mL 1† 8.59 (6.15–12.02) 16.32 (10.98–24.26) 30.09 (20.61–43.93) < 0.0001
† Model 1 (n = 51) adjusted for age, race, family history of breast cancer, parity and menarche < 12 years.
Multiple R2 = 0.56
††P-trend from linear regression models where trend is measured as a continuous value after assigning the normal weight category 0, overweight 
category 1, and obese category 2. P-values for these models where BMI is measured as a non-categorized continuous variable are available in Table 
3.
Table 1: Characteristics of the subjects (N = 51) at baseline
Characteristics Mean Median (range)
Age (y) 59.7 58.2 (49.2–78.8)
Height (cm) 163.9 163.1 (152.1–179.7)
Weight (kg) 74.8 73.2 (42.1–117.4)
BMI (kg/m2) 27.8 26.9 (17.7–42.5)
Total body fat (g) 29,744 26,808 (7,942–55,756)
Central fat (g) 13,830 13,234 (3,056–26,396)
Peripheral fat (g) 14,299 12,476 (4,163–29,507)
Lean mass (g) 39,608 38,973 (29,651–53,548)
% Body Fat 41.3% 42.5% (17.8%–55.7%)
Age at menarche (yrs) 12.7 13 (10–16)
Duration of menses (yrs) 33.3 35 (12–45)
Years since last menses 13.1 12 (1–38)
Parity (# of children) 3 2 (0–8)
†Age at first birth (yrs) 23.2 22 (16–36)
Leptin, ng/dL 19.8 17.5 (2.9–78.2)
Characteristics No (%)
Race
White 38 (74.5%)
Black 11 (21.6%)
Asian 2 (3.9%)
Menopause type
Natural 39 (76.5%)
Hysterectomy 12 (23.5%)
Family history of breast cancer
Yes 11 (21.5%)
† Based on n = 43 subjectsNutrition Journal 2007, 6:3 http://www.nutritionj.com/content/6/1/3
Page 5 of 7
(page number not for citation purposes)
3 for all the Model 2s (except lean mass) demonstrate that
BMI, percent body fat, central fat and peripheral fat mod-
els are all associated with serum leptin concentrations.
Discussion
The objective of the study was to identify the relationship
between well-defined measures of body fat distribution
and lean body mass and circulating leptin concentrations
in healthy postmenopausal women. Our results showing
that postmenopausal women with higher levels of adipos-
ity have higher concentrations of serum leptin confirm the
findings from several previous reports which showed pos-
itive correlations between adiposity and leptin concentra-
tions [8,9,27-30]. Higher lean mass was also associated
with higher serum leptin concentrations, albeit less
strongly so than for adiposity measures. To our knowl-
edge, this is the first study to evaluate the associations
between DEXA body fat distributions and lean body mass
in relation to serum leptin concentrations in healthy post-
menopausal women not on HRT under controlled dietary
conditions in which energy was balanced to maintain
weight of the women. Havel et al. [27] found that post-
menopausal women (n = 38) (about half of whom were
on HRT) kept on a weight maintenance diet with variable
fat content found BMI correlated significantly with
plasma leptin levels, and that overweight and obese
women compared to normal weight women had signifi-
cantly higher plasma leptin levels. Thus, our study is in
agreement with Havel et al. [27] regarding BMI and per-
cent body fat. However, because we used DEXA scans, our
study had a larger array of adiposity measures, and our
study also had a larger sample size.
Although our study showed that obese women, compared
to normal weight women had a greater than three-fold
increase in serum leptin concentrations, we also found
evidence that both measures of central and peripheral
body fat provided additional predictive information
beyond that achieved by BMI and other breast cancer risk
factors.
Our adiposity measures are on different scales and it is dif-
ficult for example, to compare changes of one percent in
body fat versus one kg body fat versus one BMI unit, thus
we also used multiple R2 values to summarize these asso-
ciations. The multiple R2 values from the linear regression
models reflect the percent variance explained by each of
the adiposity variable models (BMI, percent body fat, cen-
tral and peripheral fat, and lean mass), all adjusted for the
covariates, so that they can be compared. Looking at the
multiple R2 values, we found the percent body fat model
explains a largest proportion (more than 80%) of the var-
iance associated with serum leptin concentrations, and
thus appear to be very strongly associated with serum lep-
tin concentrations. However, all of the R2 values in Table
3, except for lean mass, are very high; thus, we conclude
that a simple measure – BMI, which is commonly used in
epidemiologic studies – captures a large percent of the var-
iance associated with serum leptin concentrations.
In addition to the previous studies which suffer from
inadequate control of diet and energy balance (known
confounders of leptin levels) [12-14], in postmenopausal
women the influence of HRT on circulating leptin concen-
trations has not been well defined [3,29,31]. Studies by Di
Table 3: Associations of BMI, percent body fat, central fat (trunk fat), peripheral fat, and lean mass with serum leptin concentrations
Leptin, ng/mL
Δ (95% C.I.) P-value Multiple R2
BMI
Model 1 10.65 (8.16–13.19) < 0.0001 0.68
Model 2
% Fat
Model 1 7.77 (6.56–8.98) < 0.0001 0.82
Model 2 7.20 (4.72–9.75) < 0.0001 0.82
Central fat
Model 1 11.93 (9.72–14.18) < 0.0001 0.77
Model 2 11.58 (5.87–17.61) 0.0002 0.77
Peripheral fat
Model 1 10.55 (8.33–12.81) < 0.0001 0.72
Model 2 7.98 (2.13–14.16) 0.01 0.73
Lean mass
Model 1 8.61 (3.76–13.68) 0.001 0.31
Model 2 -0.85 (-4.81–3.25) 0.68 0.68
Δ - Percent change for serum leptin concentration for a one-unit change in each of the adiposity measures (i.e., percent change in leptin 
concentration per one-unit change in BMI, per 1% increase in total body fat, per 1 kg increase in central and peripheral fat and lean mass).
Model 1: Adjusted for age, race, family history of breast cancer, parity and menarche < 12 years
Model 2: Model 1 + BMINutrition Journal 2007, 6:3 http://www.nutritionj.com/content/6/1/3
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Carlo et al. [32] and Tommaselli et al. [33] show that the
use of 17 β-estradiol and other estrogenic compounds
such as tibolone and raloxifene prevent postmenopausal
body composition changes without significant changes in
serum leptin concentrations. Our findings support the
view that increased adiposity measured as BMI, percent
body fat, central and peripheral fat are all associated with
increased leptin exposure in non-smoking postmenopau-
sal women not on HRT. Because the women in our study
population were non-smokers and not on hormone treat-
ments, the results may not be generalizable to all post-
menopausal women.
Since increased BMI [4] and central fat [34] are associated
with increased risk for breast cancer in prospective studies,
increased leptin exposure associated with obesity and cen-
tral adiposity could explain the greater incidence of breast
cancer in overweight or obese postmenopausal women.
This idea is also supported by the findings from several
experimental studies in which leptin stimulated breast
carcinogenesis [19,22,35]. However, very few epidemio-
logic studies have assessed leptin concentrations in rela-
tion to breast cancer risk. Two small case-control studies,
one in postmenopausal [36] and the other in premeno-
pausal [37] women, and a single prospective study [38]
found no association between leptin and breast cancer.
Thus, more epidemiological studies are clearly needed to
confirm the leptin-breast cancer association in postmeno-
pausal women.
Although our study is limited by its cross-sectional design
and modest sample size, the strengths of this study
include a homogeneous study population (eg, smokers
and women taking HRT were excluded) and measurement
stability, which resulted from the use of a carefully con-
trolled diet adjusted to maintain body weight. The DEXA
scans employed are considered a reference method for
body composition analysis [39]. Although our study was
conducted within the control (0 g) segment of the alcohol
trial, like all cross-over studies, there may be residual treat-
ment effects and for these reasons the design included a
two-five week washout period. We previously reported
that alcohol treatment (15–30 g/d) increased serum leptin
levels in these postmenopausal women [26].
In conclusion, our study demonstrated that serum leptin
concentrations showed striking differences by adiposity
levels. Increased exposure to leptin was observed for
increased adiposity determined by BMI, percent body fat,
central and peripheral fat as well as lean body mass.
Although BMI and DEXA adiposity (percent body fat, cen-
tral fat and peripheral fat) are highly correlated in this
cross-sectional study, it remains for further studies to con-
firm and refine our observations regarding: (i) percent
body fat as the best adiposity-related predictor of serum
leptin, and (ii) the independent value of central body fat
in this prediction even after adjustment for BMI. Because
of the well-known arguments for limitations in the use of
BMI [40], such as BMI does not discriminate between
muscle and fat, these points are particularly important to
sort out. For example, for a given BMI, Asians have higher
body fat content and higher risk for conditions such as
diabetes, high blood pressure and heart disease [41]. In
addition, prospective studies of adiposity including BMI,
other anthropometric measures, and DEXA will still be
needed to fully assess the effects of adiposity on diseases
in postmenopausal women, including not only breast
cancer but also other major causes of morbidity and mor-
tality such as osteoporosis, diabetes and heart disease.
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